Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Revenue of Xenetic Biosciences, Inc. (XBIO)
Revenue in 2023 (TTM): $2.54 M
According to Xenetic Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $2.54 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Xenetic Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.54 M | $2.54 M | $-4,515,720 | $-4,134,578 | $-4,134,578 |
| 2022 | $1.71 M | $1.68 M | $-6,690,865 | $-6,552,353 | $-6,386,798 |
| 2021 | $1.16 M | $1.13 M | $-5,711,283 | $-5,645,179 | $-5,544,712 |
| 2020 | $436.94 K | $436.94 K | $4.58 M | $-13,811,984 | $-10,893,466 |
| 2019 | $17.07 K | $17.07 K | $-6,292,584 | $-12,775,025 | $-15,949,915 |
| 2018 | $ | $-15,827 | $-7,260,500 | $-7,300,458 | $-7,300,458 |
| 2017 | $7.59 M | $7.43 M | $-3,569,530 | $-3,595,132 | $-3,595,132 |
| 2016 | $3 M | $2.96 M | $-47,394,119 | $-54,206,106 | $-54,206,106 |
| 2015 | $ | $-56,115 | $-9,764,207 | $-12,507,471 | $-12,507,471 |
| 2014 | $ | $ | $-12,817,118 | $-14,307,104 | $-14,307,104 |
| 2013 | $1000 K | $991.57 K | $-8,526,582 | $-8,579,246 | $-8,579,246 |
| 2012 | $293.6 K | $248.77 K | $-5,084,344 | $-6,328,340 | $-6,328,340 |